Metamizol for the Treatment of Neoplastic Chronic Pain

NCT ID: NCT02181920

Last Updated: 2014-07-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE4

Total Enrollment

6 participants

Study Classification

INTERVENTIONAL

Study Start Date

2000-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study to evaluate the efficacy of metamizole in reducing morphine requirements in patients with moderate to severe chronic cancer pain in comparison to administration of placebo or diclofenac.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Metamizole - Diclofenac

metamizole followed by diclofenac

Group Type EXPERIMENTAL

Metamizole

Intervention Type DRUG

Diclofenac

Intervention Type DRUG

Diclofenac placebo

Intervention Type DRUG

Metamizole placebo

Intervention Type DRUG

Diclofenac - Metamizole

diclofenac followed by metamizole

Group Type EXPERIMENTAL

Metamizole

Intervention Type DRUG

Diclofenac

Intervention Type DRUG

Diclofenac placebo

Intervention Type DRUG

Metamizole placebo

Intervention Type DRUG

Metamizole - Placebo

metamizole followed by placebo

Group Type EXPERIMENTAL

Metamizole

Intervention Type DRUG

Diclofenac placebo

Intervention Type DRUG

Metamizole placebo

Intervention Type DRUG

Placebo - Metamizole

placebo followed by metamizole

Group Type EXPERIMENTAL

Metamizole

Intervention Type DRUG

Diclofenac placebo

Intervention Type DRUG

Metamizole placebo

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Metamizole

Intervention Type DRUG

Diclofenac

Intervention Type DRUG

Diclofenac placebo

Intervention Type DRUG

Metamizole placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Hospitalized patients with neoplastic chronic pain requiring morphine treatment

Exclusion Criteria

* Karnofsky index less than 30%
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1093.14

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Paracetamol for Cancer Pain
NCT01313247 UNKNOWN PHASE4
Acetaminophen for Cancer Pain
NCT00152854 COMPLETED PHASE3